May 3, 2018 / 10:59 PM / 22 days ago

BRIEF-Mallinckrodt Reports On FDA Joint Advisory Committee Meeting For Stannsoporfin

May 3 (Reuters) - Mallinckrodt Plc:

* MALLINCKRODT REPORTS ON FDA JOINT ADVISORY COMMITTEE MEETING FOR STANNSOPORFIN FOR THE TREATMENT OF NEWBORNS AT RISK OF DEVELOPING SEVERE JAUNDICE

* FDA COMMITTEE RECOMMENDED RISK-BENEFIT PROFILE OF STANNSOPORFIN DOES NOT SUPPORT APPROVAL FOR TREATMENT OF NEWBORNS ≥35 WEEKS OF GESTATIONAL AGE

* GIVEN THE OUTCOME OF MEETING, THE COMPANY IS EVALUATING ALTERNATIVES FOR THIS DEVELOPMENT PROGRAM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below